Company profile: Diasome
1.1 - Company Overview
Company description
- Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
Products and services
- Hepatocyte Directed Vesicles (HDV): Liver-targeted technology that directs insulin to hepatocytes to improve delivery and efficacy, aiming to reduce hypoglycemia risk in diabetes patients
- OPTI-2 Phase 2b Trial: Phase 2b clinical study assessing the effectiveness of HDV insulin specifically in patients with Type 1 diabetes
- Insulin Pump Study: Phase 2 crossover study comparing HDV added to rapid-acting insulin versus rapid-acting insulin alone in patients using continuous subcutaneous insulin infusion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diasome
Adocia
HQ: France
Website
- Description: Provider of biotechnology therapies specializing in tissue regeneration and diabetes treatments, developing medicines with already-approved therapeutic proteins. Offerings include BioChaperone Lispro ultra-rapid insulin, BioChaperone Combo glargine+lispro, AdoShell Islets hydrogel implant, M1Pram and BioChaperone LisPram co-formulations, and AdOral Sema oral semaglutide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adocia company profile →
Embecta
HQ: United States
Website
- Description: Provider of diabetes healthcare products and services, offering insulin syringes in various sizes, including 6mm needles and BD Veo with BD Ultra-Fine markings; BD AutoShield Duo pen needles with dual-end shields; accessories to support injections; and embassador Companion 24/7, a digital platform with educational content, health management tools, and diabetes-friendly recipes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embecta company profile →
Fractyl Health
HQ: United States
Website
- Description: Provider of curative therapies for metabolic diseases, including Revita, a therapy designed to modify duodenal dysfunction via hydrothermal ablation to restore metabolic health, and Rejuva, a preclinical AAV gene therapy platform aimed at improving islet function for long-term remission of T2D and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fractyl Health company profile →
Diakine Therapeutics
HQ: United States
Website
- Description: Provider of novel immune modulators for the treatment of diabetes and related complications, commercializing therapeutics with potential to stop disease progression and reverse damage; a development-stage company with programs including adjunct therapy to islet.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diakine Therapeutics company profile →
Intuity Medical
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems for diabetes management, featuring the POGO Automatic Monitor that automatically lances, collects blood, and provides results with a single press using 10-test cartridges that integrate lancets and test strips, and the Patterns app to sync, track, visualize trends, share readings, send emergency notifications, and integrate with other health apps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intuity Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diasome
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diasome
2.2 - Growth funds investing in similar companies to Diasome
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diasome
4.2 - Public trading comparable groups for Diasome
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →